CTSO Cytosorbents Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1175151 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.1%
TTM net income YoY-84.6%
TTM EPS YoY-61.1%
Revenue 3-yr CAGR0.8%
Net income 3-yr CAGR—
Margins
Gross margin71.6%
Operating margin-34.7%
Net margin-48.9%
FCF margin-25.0%
EBITDA margin-32.1%
Returns
ROE-336.2%
ROA-42.4%
ROIC (approx.)-73.4%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets102.0%
Debt / equity—
Current ratio0.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $37.06M | $35.59M | $31.08M | $34.69M | $43.17M |
| Cost of revenue | $10.57M | $10.71M | $9.13M | $13.96M | $11.05M |
| Gross profit | $26.49M | $24.89M | $21.95M | $20.73M | $32.12M |
| R&D expense | — | — | $15.73M | $15.12M | $16.38M |
| SG&A expense | $35.65M | $33.73M | $38.31M | $34.29M | $35.75M |
| Operating income | -$14.75M | -$16.45M | -$31.95M | -$31.52M | -$22.74M |
| Pretax income | -$8.60M | -$22.41M | -$30.06M | -$33.91M | -$25.29M |
| Income tax | -$401,000 | -$1.69M | -$813,739 | -$1.09M | -$736,003 |
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | -$24.56M |
| EBITDA | -$13.52M | -$15.12M | -$30.49M | -$30.64M | -$22.01M |
| EPS (basic) | -0.13 | -0.38 | -0.65 | -0.75 | -0.57 |
| EPS (diluted) | -0.13 | -0.38 | -0.65 | -0.75 | -0.57 |
| Weighted avg. shares (diluted) | 62.23M | 54.43M | 44.66M | 43.57M | 43.36M |
| Balance sheet | |||||
| Cash & equivalents | $6.25M | $9.76M | $15.62M | $23.83M | $53.83M |
| Receivables | $7.55M | $7.32M | $6.06M | $5.66M | $4.52M |
| Inventory | $5.28M | $2.73M | $3.38M | $3.46M | $4.77M |
| Current assets | $20.63M | $21.60M | $25.40M | $33.76M | $64.30M |
| PP&E, net | $7.82M | $9.00M | $10.06M | $10.74M | $5.15M |
| Intangibles | $3.23M | $3.72M | $3.91M | $4.39M | $4.70M |
| Total assets | $44.18M | $47.37M | $52.96M | $63.23M | $89.52M |
| Current liabilities | $9.71M | $9.82M | $14.04M | $9.71M | $13.69M |
| Short-term debt | — | — | $2.50M | — | — |
| Long-term debt | $16.67M | $14.00M | $2.54M | $5.00M | — |
| Total debt | $16.67M | $14.00M | $5.04M | $5.00M | — |
| Total liabilities | $38.28M | $36.27M | $29.48M | $27.86M | $26.94M |
| Shareholders' equity | $5.90M | $11.11M | $23.48M | $35.37M | $62.58M |
| Net debt | $10.42M | $4.23M | -$10.57M | -$18.83M | — |
| Shares outstanding | 62.80M | 54.83M | 54.24M | 43.64M | 43.64M |
| Cash flow statement | |||||
| Operating cash flow | -$12.38M | -$14.43M | -$21.66M | -$28.23M | -$14.01M |
| Capital expenditure | $164,000 | $284,000 | $538,115 | $6.09M | $3.64M |
| Free cash flow | -$12.54M | -$14.71M | -$22.19M | -$34.32M | -$17.65M |
| Investing cash flow | -$415,000 | -$669,000 | -$936,236 | -$6.46M | -$4.28M |
| Financing cash flow | $9.31M | $9.33M | $14.47M | $4.96M | $715,199 |
| Depreciation & amortization | $1.23M | $1.33M | $1.46M | $882,621 | $731,578 |
| Stock-based compensation | $2.77M | $3.76M | $4.16M | $3.42M | $4.02M |
Free plan shows the latest 5 periods; Pro shows all 29 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.